Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Current Deferred Revenue: 2019-2024

Historic Current Deferred Revenue for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $306,000.

  • Silence Therapeutics' Current Deferred Revenue rose 106.41% to $301,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $301,000, marking a year-over-year increase of 106.41%. This contributed to the annual value of $306,000 for FY2024, which is 95.34% down from last year.
  • According to the latest figures from FY2024, Silence Therapeutics' Current Deferred Revenue is $306,000, which was down 95.34% from $6.6 million recorded in FY2023.
  • Silence Therapeutics' 5-year Current Deferred Revenue high stood at $21.9 million for FY2020, and its period low was $306,000 during FY2024.
  • Moreover, its 3-year median value for Current Deferred Revenue was $6.6 million (2023), whereas its average is $5.9 million.
  • As far as peak fluctuations go, Silence Therapeutics' Current Deferred Revenue soared by 591.67% in 2020, and later plummeted by 95.34% in 2024.
  • Yearly analysis of 5 years shows Silence Therapeutics' Current Deferred Revenue stood at $21.9 million in 2020, then crashed by 73.30% to $5.8 million in 2021, then spiked by 87.74% to $11.0 million in 2022, then tumbled by 40.10% to $6.6 million in 2023, then tumbled by 95.34% to $306,000 in 2024.